Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Number of holders
-
21
-
Total 13F principal, excl. options
-
96,675,000
-
Principal change
-
-114,875,000
-
Total reported value, excl. options
-
$135,757,022
-
Value change
-
-$192,335,574
-
Number of buys
-
6
-
Number of sells
-
17
-
Price
-
$1.40
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q1 2021
As of 31 Mar 2021 APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 had 21 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $96,675,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), MACKAY SHIELDS LLC, JPMORGAN CHASE & CO, AMERIPRISE FINANCIAL INC, WELLS FARGO & COMPANY/MN, LMR Partners LLP, Opti Capital Management, LP, CAPSTONE INVESTMENT ADVISORS, LLC, Farallon Capital Management, L.L.C., and WOLVERINE ASSET MANAGEMENT LLC.
This table shows 21 bond principal holders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.